Combination immunotherapy that is used to treat patients with malignant melanoma or non–small cell lung cancer has received FDA approval for adults with unresectable malignant pleural mesothelioma.
Nivolumab, marketed as Opdivo, and ipilimumab, marketed as Yervoy, comprise the first regimen approved for mesothelioma in 16 years. Treatment with pemetrexed in combination with cisplatin was approved in 2004.